CA
ADCT icon

Clearstead Advisors’s ADC Therapeutics ADCT Stock Holding History

Clearstead Advisors’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$39 Buy
+36
New +$105 ﹤0.01% 3515
2025
Q4 		– Sell
-1
Closed -$4 – 2742
2025
Q3 		$4 Buy
+1
New +$3 ﹤0.01% 3065

Other funds holding ADCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
SCTC
Sanibel Captiva Trust Company Sanibel, Florida $4.02B AUM 34.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $11.7B AUM 87.29% 1-Year Est. Return
RWP
Revolve Wealth Partners Hackensack, New Jersey $965M AUM 22.88% 1-Year Est. Return
WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.48B AUM 24.77% 1-Year Est. Return
DIM
DLK Investment Management Solana Beach, California $235M AUM 12.41% 1-Year Est. Return

Clearstead Advisors's ADCT Position: Q2 2026 in Review

Clearstead Advisors opened a new position in ADC Therapeutics (ADCT) in Q2 2026: 36 shares worth $39. The stake represents ﹤0.01% of the portfolio and ranks #3515 among its holdings. This is a return to the name: Clearstead Advisors previously reported a position in ADCT as recently as Q3 2025.

Clearstead Advisors first reported a position in ADCT in Q3 2025 and has held it in 2 quarters since. 38 funds tracked by Wall St. Rank hold ADCT as of Q2 2026.

  • Clearstead Advisors held 36 shares of ADC Therapeutics worth $39 as of Q2 2026.
  • ADC Therapeutics was a new Clearstead Advisors position in Q2 2026.
  • ADC Therapeutics made up ﹤0.01% of Clearstead Advisors's portfolio in Q2 2026, its #3515 holding.
  • Clearstead Advisors first reported a position in ADC Therapeutics in Q3 2025 and has held it in 2 quarters since.
  • 38 funds tracked by Wall St. Rank held ADC Therapeutics as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.